The pharmaceutical industry is set for a game-changing innovation as WuXi STA, a global CRDMO, unveils a new high potency (HP), fully automated sterile injectable manufacturing line at its Wuxi City site. With an annual capacity of 12 million units, this state-of-the-art facility significantly boosts the company’s capabilities in producing high potency pharmaceuticals.
Safety and quality are paramount in this groundbreaking manufacturing line. It adheres to Occupational Exposure Limits (OEL) as low as 10 ng/m3, making it a highly secure environment for manufacturing potent drugs. Moreover, the company has implemented fully enclosed isolation systems and automated filling machines, virtually eliminating human intervention and reducing potential cross-contamination risks.
But this is just the tip of the iceberg. WuXi STA’s vision extends beyond this new launch. By 2024, the company plans to add two more injectable manufacturing lines at the Wuxi City site, signaling its commitment to industry advancement and patient well-being. As Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, puts it, the company is dedicated to “accelerating pharmaceutical development and bringing new therapeutics for patients worldwide.”
